Connect
MJA
MJA

Diagnosing bipolar disorder: how can we do it better?

Michael Berk, Lesley Berk, Kirsteen Moss, Seetal Dodd and Gin S Malhi
Med J Aust 2006; 184 (9): 459-462. || doi: 10.5694/j.1326-5377.2006.tb00319.x
Published online: 1 May 2006

Difficulties and delay in the diagnosis of bipolar disorder impede effective treatment and amplify the burden of illness on the individual, the family and society.1 The 2000 National Depressive and Manic-Depressive Association survey2 estimated the prevalence of bipolar I and II disorder in the United States to be 3.4%. Of people with bipolar disorder, almost a third (31%) had been incorrectly diagnosed as suffering from unipolar depression and, in nearly half (49%), the condition was both unrecognised and undiagnosed. Remarkably, just over a third (35%) of these individuals had been symptomatic for more than 10 years before the correct diagnosis was made.

The 2003 Access Economics report for SANE Australia on the costs of bipolar disorder in Australia1 confirmed that a 10-year gap before correct diagnosis is not uncommon. The SANE report found that over two-thirds (69%) of people with bipolar disorder were misdiagnosed (on average, three to four times) before receiving the correct diagnosis. The most common alternative diagnoses included depression (60%), anxiety disorder (26%), schizophrenia (18%) and borderline or antisocial personality disorders (17%).1 Not surprisingly, a number of studies involving extended periods of follow-up3 have illustrated that there is a substantial switch in diagnosis from unipolar to bipolar disorder over time.4

We believe that correct diagnosis of bipolar disorder and appropriate early intervention is possible and likely to enhance long-term patient outcomes (Box 1). We can increase the detection of bipolar disorder, and thus improve outcomes, by asking and answering further questions about factors that may contribute to problems in diagnosis. For example:

We hope that our discussion of issues related to these questions will assist clinicians to diagnose bipolar disorder earlier and more accurately.

Diagnostic systems

There is no definitive diagnostic system for bipolar disorder. Significant differences between definitions of “bipolar disorder” in the American Psychiatric Association’s DSM-IV17 and the World Health Organization’s ICD-1018 disease classifications mean that some patients will be diagnosed with bipolar disorder under one system but not the other. There are also a number of controversial areas within the DSM system (Box 2). Additionally, inability to confirm a diagnosis of bipolar disorder may be unavoidable, as neither diagnostic system allows the diagnosis of bipolar disorder until a full episode of mania or hypomania has occurred, yet many patients will commence their illness with an episode of depression, and may have had hypomanic symptoms that, for example, did not meet criteria for duration of symptoms. Therefore, there is intrinsic diagnostic delay.

Basic diagnostic indicators

Despite the difficulty presented by current diagnostic systems, we believe that good clinical practice requires that when a patient presents with a depressive episode the clinician should have an index of suspicion that the episode may be part of bipolar disorder. Careful evaluation and constant vigilance, coupled with knowledge of potential indicators of bipolarity, are likely to improve diagnosis.

A number of authors have attempted to identify clinical indicators suggestive of bipolarity in individuals presenting with depression (Box 3). These include strong indicators, such as family history, and suggestive features, such as postpartum onset and a seasonal pattern. Simple screening questionnaires such as the Mood Disorder Questionnaire may be useful in suggesting an appropriate diagnosis of bipolarity, particularly in primary care settings.19 Furthermore, an awareness of the multiple factors that can obfuscate diagnosis of bipolar disorder (eg, complex phenomenology, age at onset, comorbidity and the heterogeneity of bipolar disorder presentations) can help in correct diagnosis. Early intervention with appropriate treatment is likely to enhance long-term outcomes.

Specific clinical issues
Emergence of symptoms

The emergence of symptoms of bipolar disorder may present a confusing picture for both clinician and patient. The onset of bipolar disorder is frequently insidious, with relatively minor, predominantly depressive, oscillations in mood, gradually giving way to episodes of depression. Features such as increased energy, elevated mood, disinhibition and racing thoughts are common antecedents to the emergence of a full-blown manic episode. Indeed, many patients who later develop bipolar illness present with a prodrome of behavioural mood problems long before an identified episode of illness. Equally, many patients experience major episodes of illness without a clear prodrome.20 There may be substantial delay in seeking help because patients may not understand the nature of their symptoms, or may simply be embarrassed or fearful of potential stigma.5 When help is sought, it is typically for depressive rather than manic or hypomanic symptoms, and yet it is the latter that serve as the signature of bipolar disorder. This creates a paradoxical situation in which the presenting symptoms of the illness are often not those needed to define or diagnose bipolar disorder.

Family history

Family history is an important diagnostic indicator (Box 3). However, high rates of unipolar depression among individuals with a family history of bipolar disorder cause difficulty, as the index episode of bipolar disorder is typically depressive.

Age at onset

There are particular difficulties in diagnosing bipolar disorder in younger people, partly because of a low base rate and variability in clinical presentation, but also because of overlap in phenomenology with other disorders.23 Particularly problematic is the boundary between bipolarity and attention deficit hyperactivity disorder, with comorbidity rates estimated to be as high as 87%.24 In adolescents, the impact of development on symptom expression, resulting in subtly different phenomenology, is a further complication.25 Clinical features in young people that may aid differentiation include higher rates of mixed mania (55%) and rapid cycling (87%).24

In children, the phenomenology is again somewhat different, with less discrete episodes of mania or depression and high rates of mixed states, dysphoria and rapid cycling.26 Irritability persisting through episodes, with aggressive behaviour and temper outbursts, is common, with children frequently presenting as emotionally labile and explosive.

A spectrum of disease

Few patients are “classically bipolar”, alternating between episodes of “pure” mania and “pure” depression. Instead, an array of illness patterns occur, particularly mixed states, rapid cycling and diverse comorbidities. Moreover, bipolar disorder can be heterogeneous in severity. Mild variants such as cyclothymia can occur.

Bipolar spectrum

The concept of a “bipolar spectrum”28 complicates the diagnosis of bipolar disorder. This pertains to a substantial group of individuals whose symptoms lie in a grey area between those of unipolar and bipolar disorder. The unclear diagnostic boundary between these groups limits the selection of appropriate therapeutic algorithms. Similarly, there is overlap among people presenting with psychotic symptoms, incorporating schizophrenia and bipolar I disorder. A further “spectral link” occurs between bipolar disorder and personality, with an overlap existing particularly with borderline personality disorder. The bipolar spectrum is particularly common in certain subgroups of patients, with rates of up to 72% in patients with atypical depression29 and 50% in patients with treatment-resistant depression.30 Within general practice, a quarter of patients with depression or anxiety have bipolarity.31

Mixed episodes

We believe one of the most common pitfalls in the diagnosis of bipolar disorder is that of mixed symptoms.32 In a mixed episode, criteria are met for both manic and depressive episodes simultaneously. In practice, this manifests as the intrusion of depressive symptoms into a predominantly manic presentation or the intrusion of manic symptoms into what looks like a depressive presentation. Research suggests33 that this delays diagnosis, perhaps because the predominant complaint is that of depressed or dysphoric mood, with key manic features (eg, increased motor drive, reduced sleep, crowded or racing thoughts) receding into the background. Mixed states have particularly high rates of comorbidity with anxiety, personality disorders and the use of antidepressants and substance misuse. An implication of this is that inappropriate diagnosis may drive inappropriate therapy, which can create clinical scenarios that are more difficult to recognise. One of the important differences between mixed and pure mania is that suicidality is a far greater risk in the former.34

Conclusion

Accurate diagnosis of bipolar disorder is prone to many pitfalls, especially when trying to make a diagnosis on the basis of a clinical interview in which the patient presents in a single phase of a complex illness. Extended follow-up and collateral information greatly assist in the diagnostic process. Making a correct diagnosis is essential so that a patient can be given the right treatment and obtain a good treatment outcome. There is considerable controversy over the boundaries of the diagnostic definition of bipolar disorder. Current research is focusing on defining these boundaries.

1 Bipolar disorder (BD): why does early diagnosis matter?

Disruption to daily life

People with undiagnosed BD frequently suffer continued chaotic existence. With the most common age of occurrence of illness being in adolescence or young adulthood, undiagnosed BD can disrupt the normal development of social skills and relationships and have a negative impact on education and earning potential.5

Benefits of early initiation of treatment

Emerging evidence suggests that the course and outcome of BD are worsened by persistent illness, whereas early intervention results in a more favourable outcome.2 Studies of people with BD have shown that earlier initiation of lithium therapy is associated with greater response to the treatment.6,7 BD is associated with neuropsychological impairment, and recent studies of mood stabilisers7 and atypical antipsychotics8 point to potential neuroprotective aspects of these treatments. Accurate diagnosis and appropriate treatment may also be protective against the functional impairment associated with BD.9

Harmful effects of inappropriate treatment

Optimal outcomes are contingent on appropriate therapy, and an inaccurate diagnosis is likely to lead to the initiation of inappropriate therapy. Ghaemi et al,10 comparing people with BD and unipolar disorder, found that a higher proportion of those with BD failed to respond to antidepressant therapy, or had an initial response but subsequently lost response, or had a manic switch after initiation of antidepressant therapy. There is also a significant risk of inducing rapid cycling in people who are misdiagnosed as having unipolar depression and treated with antidepressants.11 Recent long-term prospective studies examining the risk of switching into mania or hypomania after antidepressant treatment have shown far higher rates of switching than previously reported.12

Risk of suicide

There is an enduring risk of suicide in patients with BD, which may be higher than the risk for other mental disorders13 and is 12 times higher than in the general population.14 Studies have demonstrated the protective effects of appropriate lithium treatment on suicide risk.15,16

  • Michael Berk1,2
  • Lesley Berk3
  • Kirsteen Moss4
  • Seetal Dodd1
  • Gin S Malhi4

  • 1 Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, VIC.
  • 2 ORYGEN Research Centre, Melbourne, VIC.
  • 3 Collaborative Therapy Unit, Mental Health Research Institute, University of Melbourne, Melbourne, VIC.
  • 4 School of Psychiatry, Black Dog Institute, University of New South Wales, Sydney, NSW.


Correspondence: seetald@barwonhealth.org.au

Competing interests:

Michael Berk has received consultant fees, speaker fees and/or educational grants from various pharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Mayne Pharma, Novartis, Organon, Pfizer, Sanofi-Synthelabo, Servier, Solvay and Wyeth. Seetal Dodd has received consultant fees and travel assistance to attend meetings from Eli Lilly, and speaker fees and/or educational grants from Bristol-Myers Squibb, Eli Lilly, Mayne Pharma, Novartis, Organon and Servier.

  • 1. Access Economics, for SANE Australia. Bipolar disorder: costs. An analysis of the burden of bipolar disorder and related suicide in Australia. Melbourne: Access Economics, for SANE Australia, 2003. Available at: http://www.accesseconomics.com.au/reports/bipolar.pdf (accessed Mar 2006).
  • 2. Hirschfeld, RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64: 161-174.
  • 3. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry 2001; 158: 1265-1270.
  • 4. Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord 2005; 84: 149-157.
  • 5. Lewis L. Patient perspectives on the diagnosis, treatment and management of bipolar disorder. Bipolar Disord 2005; 7: 33-37.
  • 6. Franchini L, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999; 249: 227-230.
  • 7. Chang K, Karchemskiy A, Barnia-Goraly N, et al. Reduced amygdalar gray matter volume in familial pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 565-573.
  • 8. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361-370.
  • 9. Fagiolini A, Kupfer DJ, Masalehdan A, et al. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005; 7: 281-285.
  • 10. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004; 161: 163-165.
  • 11. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000; 61: 804-808, quiz 809.
  • 12. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239.
  • 13. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003; 17: 491-511.
  • 14. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: 205-228.
  • 15. Muller-Oerlinghausen B, Ahrens B, Volk J, et al. Reduced mortality of manic-depressive patients in long-term lithium treatment: an international collaborative study by IGSLI. Psychiatry Res 1991; 36: 329-331.
  • 16. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172.
  • 17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: 4th edition (DSM-IV). Washington, DC: APA, 1994.
  • 18. World Health Organization. International statistical classification of diseases and related health problems: 10th revision (ICD-10). Geneva: WHO, 1992.
  • 19. Hirschfeld RM. The Mood Disorder Questionnaire: a simple, patient-rated screening instrument for bipolar disorder. Prim Care Companion J Clin Psychiatry 2002; 4: 9-11.
  • 20. Shaw JA, Egeland JA, Endicott J, et al. A 10-year prospective study of prodromal patterns for bipolar disorder among Amish youth. J Am Acad Child Adolesc Psychiatry 2005; 44: 1104-1111.
  • 21. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420-426.
  • 22. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 1999; 56: 617-626.
  • 23. Kim EY, Miklowitz DJ. Childhood mania, attention deficit hyperactivity disorder and conduct disorder: a critical review of diagnostic dilemmas. Bipolar Disord 2002; 4: 215-225.
  • 24. Geller B, Zimerman B, Williams M, et al. Diagnostic characteristics of 93 cases of a prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and comorbid attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2000; 10: 157-164.
  • 25. Bowring MA, Kovacs M. Difficulties in diagnosing manic disorders among children and adolescents. J Am Acad Child Adolesc Psychiatry 1992; 31: 611-614.
  • 26. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Pediatric bipolar disorder: phenomenology and course of illness. Bipolar Disord 2004; 6: 305-313.
  • 27. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004; 6: 504-518.
  • 28. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 1999; 22: 517-534, vii.
  • 29. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of “soft” bipolar (II) features in atypical depression. Compr Psychiatry 1998; 39: 63-71.
  • 30. Ghaemi SN, Sachs GS, Chiou AM, et al. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999; 52: 135-144.
  • 31. Manning JS, Haykal RF, Connor PD, Akiskal HS. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997; 38: 102-108.
  • 32. Berk M, Dodd S, Malhi GS. “Bipolar missed states”: the diagnosis and clinical salience of bipolar mixed states. Aust N Z J Psychiatry 2005; 39: 215-221.
  • 33. Akiskal HS, Hantouche EG, Azorin JM, et al. Clinical characterization of acute mania: data in 1090 patients — ‘EPIMAN-II’. Bipolar Disord 2003; 5: 27-28.
  • 34. Dilsaver SC, Chen YW, Swann AC, et al. Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994; 151: 1312-1315.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.